The purpose is to review recent insights into the impact of HIV-associated immune activation on AIDS and non-AIDS morbidity and mortality.
INTRODUCTION
The first clue that immune activation was a central feature of HIV pathogenesis came in the first case reports of AIDS in 1981, long before HIV-1 was even recognized as the cause of AIDS [1] . In this initial report, Gottlieb et al. noted that the young gay men dying of pneumocystis pneumonia in Los Angeles had not just very low CD4 þ T-cell counts, but also extraordinarily high levels of the surface marker 'T10' on their lymphocytes. This marker T10 was later renamed CD38 and became one of the most commonly used markers to assess T-cell activation in the preantiretroviral therapy (ART) era. Giorgi and colleagues [2, 3] subsequently demonstrated that greater CD38 expression on CD8 þ T cells predicted more rapid disease progression independently of CD4 þ T-cell count and the extent of viral replication (and in later work, more strongly than the degree of viral replication). It is also noteworthy that during this same period, neopterin and b2-microglobulin -markers of innate immune (and more specifically monocyte/macrophage) activation -were also found to be abnormally high in untreated HIV infection and to predict more rapid progression to AIDS, though not quite as strongly as T-cell activation [2, 4] . This was an important initial clue that whereas HIV caused generalized activation of the innate and adaptive immune systems, it was the adaptive immune defects that seemed to be playing a more important role in driving AIDS and other infectious complications. Although this may seem intuitive, it is an important insight, suggesting that several distinct pathways of immune activation differentially drive end-organ disease manifestations.
]. Indeed, early initiation of ART (within the first 6 months of infection) appears to achieve a lower immune activation set point than when ART is delayed even a few years [12, 13] . Nevertheless, even very early ART -initiated in the first few weeks of HIV infectionfails to completely normalize several pathways of innate immune activation [14] , suggesting that whereas many pathways of immune activation clearly get worse with progressive untreated infection, some irreversible drivers of immune activation are established very early. Conversely, hypercoagulability (i.e., D-dimer elevations) and some adaptive immune defects are nearly completely reversed by very early ART [ [18] . A critical issue that remains largely unaddressed is whether these putative drivers of persistent immune activation, each of which may get worse (and potentially less reversible) with progressive untreated HIV disease, are equally ameliorated by the very early initiation of ART and/or drive the same end-organ disease manifestations. Indeed, just as discrete immune activation pathways had differential prognostic capacity in the pre-ART era, not all immune activation pathways -and their root drivers -are likely to predict specific morbidities equally with suppressive ART. For example, among ARTsuppressed HIV-infected individuals in North America, innate immune activation and inflammatory markers were much more strongly predictive of mortality than T-cell activation (the opposite inference from the pre-ART era) [ . These hypotheses will be important to address to identify interventional targets to prioritize for clinical trials, the specific morbidities (or their surrogates) to include as primary outcome measures, and the specific patient populations at highest risk (i.e., those who began ART during early vs. advanced HIV infection).
SPECIFIC IMMUNOLOGIC PATHWAYS THAT PREDICT DISEASE IN HIV INFECTION

T-cell activation and dysfunction
T-cell activation -characterized as either the coexpression of CD38 and human leukocyte antigen (HLA)-DR or the intensity of CD38 expression on CD8 þ T cells -has long been established as an
KEY POINTS
Early ART appears to be most effective at decreasing infectious complications.
The degree to which early ART reverses discreet pathways of immune activation and their drivers may differ.
The extent to which discreet pathways of immune activation drive morbidity and mortality may differ according to the end-organ disease of interest and environment.
Understanding the immune activation pathways and their root drivers that are most strongly predictive of disease may help prioritize targets for interventions to pursue in clinical trials and identify individuals at highest risk. þ T cells and appears to predict subsequent mortality during ART-mediated viral suppression to a much greater degree than T-cell activation [15 & ]. The determinants of these maturational and/or proliferative effector CD8 þ T-cell defects in HIV infection remain unclear, but may provide insights into novel interventions to reverse adaptive immune defects that persist even in individuals who start ART during very early HIV infection. Indeed, approximately 1% of the immediate ART arm in START experienced an AIDS complication within 5 years of treatment initiation, despite maintaining normal CD4 þ T-cell counts. Similarly, although early ART diminished the risk of tuberculosis in the Temprano study participants with high CD4 þ T-cell counts, there was a clear additive benefit of isoniazid prophylaxis and a substantial ongoing risk of tuberculosis even in this subgroup.
Indoleamine 2,3-dioxygenase-1 (IDO) activity
The indoleamine 2,3-dioxygenase-1 (IDO) pathway is a potentially important link between innate and adaptive immune defects in HIV infection. þ T-cell depletion [42, 43] . High expression of the programmed death-1 homologue (PD-1H), which is associated with increased production of tumor necrosis factor, IL-1b, and IL-6, may also contribute to the proinflammatory state of these monocytes [44 && ]. CD16 þ nonclassical and intermediate monocytes have a high migratory capacity, which has been attributed to expression of the chemokine receptors chemokine (C-C motif) receptor type 2, CCR5, [45, 46] and chemokine (C-X3-C motif) receptor 1 [47] . Indeed, higher expression of the monocyte adhesion molecule chemokine (C-X-C motif) ligand 1 was associated with death in Strategies for Management of Antiretroviral Therapy [48 & ]. These migratory monocytes have been postulated to facilitate HIV dissemination into tissues such as the intestine and liver and contribute to reservoir establishment [49 & ]. Although ART reduces these proinflammatory monocytes [40 && ,41], it is less clear whether ART suppresses inflammatory tissue macrophages that were established prior to ART. Persistence of the HIV reservoir, microbial translocation, and coinfections despite ART may continue to stimulate inflammation in tissue macrophages.
One barrier to studying activation of monocytes is that their recovery, viability, and protein expression can be compromised during cell processing, cryopreservation, and thawing. Thus, circulating biomarkers released by activated monocytes, such as soluble CD14 (sCD14), soluble CD163 (sCD163), IL-6, neopterin, and interferon g-induced protein 10 (IP-10) are often used to identify monocyte activation.
CD14 is the lipopolysaccharide (LPS) receptor sCD14 is shed or secreted by monocytes in response to LPS stimulation, but also potentially by neutrophils and hepatocytes. Whether sCD14 is specific or quantitative for microbial translocation remains controversial [50, 51] , but the rapid decrease in sCD14 levels without changes in LPS after initiating ART suggests other inflammatory cytokines may contribute to its shedding [52] . CD163, the haptoglobin receptor, is expressed exclusively by macrophages and monocytes and its shedding is at least in part mediated by tumor necrosis factor [53] . Tissue macrophages express higher levels of CD163 than circulating monocytes, suggesting high sCD163 levels may reflect underlying tissue inflammation. Other markers of inflammation, including IL-6, IP-10, and neopterin [54] [55] [56] High levels of biomarkers of monocyte activation may reflect or even predict HIV disease progression. High plasma IP-10, IL-6, and sCD14 all consistently predict increased subsequent morbidity and mortality during ART [42, 43, 60] , and high sCD163 levels have been associated with surrogate markers of neurologic and cardiovascular disease (though perhaps not cardiovascular events [61] ), as well as all-cause mortality in a recent report [26, [57] [58] [59] 62, 63] . As many of these biomarkers of monocyte activation may be increased by smoking and/or alcohol use, these associations with morbidity and mortality may be at least in part driven by behavioral risk factors and not HIV itself, though a recent report suggests that these associations persist despite adjustment for behavioral risk factors [64] . However, similar to T-cell activation, whether the association of monocyte activation with morbidity and mortality is causative or correlative remains unclear.
TYPE I INTERFERONS
Type I interferons may contribute to monocyte activation, and thereby facilitate HIV dissemination and disease progression. Data from the Centre for the AIDS Programme of Research in South Africa 004 study suggest that interferon signaling may render women more susceptible to infection. Women with detectable macrophage inflammatory protein (MIP)-1a and MIP-1b and higher levels of IP-10, all of which are upregulated by interferons, in cervicovaginal lavage were at increased risk of HIV acquisition [65] . The increased risk is likely attributed to increased HIV target cell recruitment to the vaginal mucosa by these three chemokines [65] . However, IFNa administration prior to high-dose SIV rectal challenge delayed acquisition of systemic infection [66] . Thus, increased interferon signaling may facilitate HIV acquisition in target-limited tissues and protect against acquisition in target-rich tissues.
However, blocking type I interferons during acute SIV infection accelerates progression to AIDS and death [66] , indicating their role in inducing antiviral responses supercedes the detrimental consequences of activating monocytes and creating and recruiting target cells. Indeed, in cervical explants, polyinosinic:polycytidylic acid initiates an interferon signaling cascade through the master interferon signaling regulator, interferon regulatory factor 7, and decreases HIV replication. Interferon signaling may even be synergistic with antiretroviral drugs such as tenofovir to suppress HIV replication [67] . Moreover, genetic polymorphisms that interfere with interferon signaling are associated with rapid disease progression [68] . However, the balance of the benefits of HIV control with the potentially detrimental proinflammatory effects of type I interferons warrant consideration. IFNa upregulates Siglec-1 on monocytes and dendritic cells [69 && ], and therefore facilitates myeloid cell capture of HIV. These myeloid cells can then transfer HIV to CD4
þ T cells via cell-to-cell contact. As Siglec-1 þ cells have been identified in the perifollicular CD4 þ T-cell-rich region of the lymph node, it is not surprising that high Siglec-1 expression correlates with high plasma viral load and low CD4 þ T-cell counts [69 && ]. In addition to upregulating Siglec-1, in-vitro data suggest IFNa interferes with IL-7 and IL-2-mediated CD4 þ T-cell proliferation, and thereby further increases CD4 þ T-cell death [70] . Several studies are queued to evaluate the effects of IFNa administration or blockade using an experimental drug in the setting of suppressive ART [71] . These interventions will likely have opposite effects on immune activation and possibly on CD4 þ T-cell counts and further illuminate causal factors in CD4 þ T-cell depletion. However, these studies are not designed to assess long-term clinical consequences, including noninfectious complications and mortality.
LYMPHOID TISSUE FIBROSIS
Lymphoid tissue fibrosis begins in acute retroviral infection [72] . Studies of pathogenic nonhuman primate models demonstrated that collagen deposition in lymphoid tissue [72] begins as early as 7 days postinfection and in response to stimuli such as LPS and HIV itself. These stimuli induce an inflammatory response reflected by increased expression of the interferon-stimulated gene Mx1 and of the cell proliferation marker Ki67. Regulatory T cells are then activated to express transforming growth factor b (TGFb), the canonical driver of fibrosis. Resident fibroblasts deposit collagen I, III, fibronectin, and other components of the extracellular matrix [72] , destroying the lymph node structure. This destruction of the discrete pathway of fibroblast reticular cells that guides T cells, especially naive T cells, to the paracortical T-cell zone prevents their interaction with antigen-presenting cells and survival and proliferation signals such as IL-7. Similarly, the pathway guiding B cells to the primary follicles where they encounter follicular dendritic cells and their cognate antigens is destroyed. In contrast to pathogenic hosts, natural hosts of SIV infection do not upregulate TGFb in lymphoid tissue or develop lymphoid tissue fibrosis [73] . SIVcpz confers an intermediate phenotype in the chimpanzee, with substantial variability noted among animals and fibrosis primarily occurring in noncaptive animals [74, 75 & ]. Thus, fibrosis compromises clonal expansion of T cells and germinal center formation [73] . This fibrosis also involves the gut-associated lymphoid tissue (GALT), which may further perpetuate microbial translocation and fibrosis. As the vast majority of T cells are found in lymphatic tissue, greater lymphoid tissue fibrosis and duodenal TGFb expression correlate with lower CD4 þ T-cell counts. In the GALT, this TGFb appears to be produced by intestinal myofibroblasts in response to LPS stimulation [76 && ]. Captive chimpanzees virtually normalize their T-cell and monocyte activation, perhaps because of the lack of additional proinflammatory environment stimuli. However, increased collagen deposition in the T-cell zone of lymphoid tissue was maintained and CD4 þ T-cell counts remained decreased compared to healthy animals [75 & ]. Thus, the transient inflammation that resulted in collagen deposition in the lymphoid tissue is sufficient to suppress CD4 þ T-cell counts. In contrast, nonpathogenic SIV models without lymphoid fibrosis or microbial translocation do not progress to AIDS [73] . Ultimately, interventions to improve or prevent impaired gut integrity and increased intestinal LPS levels may reduce lymphoid fibrosis. As fibrosis limits CD4
þ T-cell recovery on ART and may impair antigen-specific responses [77] , interventions that attenuate lymphoid tissue may have pleiotropic benefits.
CONCLUSION
HIV activates several arms of the immune system, which likely gives rise to several different infectious and noninfectious disease manifestations, even during ART-mediated viral suppression. These discreet immunologic pathways, while overlapping, likely have distinct roles in mediating different disease manifestations and may even have distinct root causes. A better understanding of which pathways drive specific disease manifestations, the root causes of those pathways, and the degree to which they can be reversed by early ART initiation will help prioritize interventional targets to study and identify the populations at highest risk. This systematic approach is likely to help accelerate the development of novel interventions to further improve the health of HIV-infected individuals in the modern treatment era. 
